Clinical Investigation on the Treatment of Radiation Induced Dermatitis

Status Completed

Clinical Trial Summary

The radiotherapy after surgery reduces the risk of recurrence and death is widely used for standard treatment for cancer including breast cancer and head and neck cancer. However, radiation dermatitis is a common side effect and major adverse event of radiotherapy. Radiation induces skin inflammation resulting in redness, itchiness and peeling skin. Radiation dermatitis may be acute or chronic. Acute skin changes occur within 90 days of initiating therapy due to inflammation and DNA damage and chronic skin changes may occur after several weeks or years. Radiation-irritated skin is a treatment-induced symptom caused by radiation dose-limiting toxicity. It damages skin structure and causes a variety of symptoms of cuticle thinning, reducing of collagen in subcutaneous, sweat glands damage, sebaceous glands damage and basal membrane damage. These conditions lead patients to lost work productivity, wound care costs, social isolation, altered body image and affect a patient's quality of life and mental health both during and after treatment and even interrupts the treatment schedule. The treatment of radiation dermatitis is an essential component of radiotherapy. The common treatment includes agents and other dressing products, such as corticosteroid cream, hyaluronic acid, aloe and sucralfate, which are used to prevent or reduce severity of dermatitis. But there is no clear therapeutic or nursing guideline supporting continuous treatment of radiation dermatitis by topical agents currently. In this study, Radiation Care® gel which contain Japanese honeysuckle extract will be used in breast and head and neck cancer patients to test the safety and efficacy to prevent radiation dermatitis and alleviate their radiation-irritated skin symptoms. The primary objective of this study is to evaluate the clinical outcomes of "Radiation Care" gel application in breast cancer and head and neck cancer patients who have radiation dermatitis or radiation-irritated skin due to the radiotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04995328
Study type	Interventional
Source	China Medical University Hospital
Contact
Status	Completed
Phase	N/A
Start date	August 3, 2021
Completion date	October 7, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04059809` - Photobiomodulation for Breast Cancer Radiodermatitis	Phase 2/Phase 3
Not yet recruiting	`NCT06040983` - Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing	N/A
Withdrawn	`NCT05505214` - Topical Steroids & Bacterial Decolonization for Radiation Dermatitis	Phase 2
Withdrawn	`NCT04593914` - A Novel Skin Barrier Protectant for Acute Radiodermatitis	N/A
Completed	`NCT05450848` - StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis	N/A
Active, not recruiting	`NCT05594498` - A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients	N/A
Recruiting	`NCT04110977` - A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer	N/A
Recruiting	`NCT06158347` - Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer	N/A
Recruiting	`NCT05553392` - StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis	N/A
Active, not recruiting	`NCT04268056` - Characterization of Skin Microbiome Profile and it's Correlation to Radiation Dermatitis
Not yet recruiting	`NCT04888234` - Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis.	Phase 2
Terminated	`NCT01597921` - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer	N/A
Completed	`NCT00481884` - Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients	Phase 3
Completed	`NCT03494205` - Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis	Phase 2
Completed	`NCT05810194` - Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
Completed	`NCT03941665` - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients	N/A
Not yet recruiting	`NCT02051907` - Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis	Phase 2
Completed	`NCT02839473` - Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial	Phase 3
Completed	`NCT00573365` - LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis	N/A
Completed	`NCT00876642` - Trial Comparing Best Supportive Care to Aloe Vera Gel	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms